Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in March: Barclay’s Global Healthcare Conference Format: Presentation Date: Wednesday, March 10, 2021 Time: 4:10 p.m. ET Stifel 3 rd Annual CNS Day Format
PHILADELPHIA, March 02, 2021 (GLOBE NEWSWIRE) --Passage Bioo, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that management will participate in two upcoming virtual investor conferences in March:
Barclay’s Global Healthcare Conference
Format: Presentation
Date: Wednesday, March 10, 2021
Time: 4:10 p.m. ET
Stifel 3rd Annual CNS Day
Format: Fireside Chat
Date: Wednesday, March 31, 2021
Time: 10:00 a.m. ET
A live webcast of the presentation and fireside chat will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the Barclay’s and Stifel presentations will be available for 30 days following the fireside chat.
About Passage Bio
At Passage Bio (Nasdaq: PASG), we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at www.passagebio.com.
For further information, please contact:
Investors:
Stuart Henderson
Passage Bio
shenderson@passagebio.com
Media:
Gwen Fisher
Passage Bio
215.407.1548
gfisher@passagebio.com
